State Key Laboratory of Oral Diseases, Department of Oral Pathology, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China.
Department of Head and Neck Surgery, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, China.
Front Immunol. 2020 Sep 18;11:1721. doi: 10.3389/fimmu.2020.01721. eCollection 2020.
Over the past 10 years, cancer immunotherapy has made significant progress in multiple cancer types and has been gradually been applied to clinical cancer care, in which the programmed cell death protein-1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway is one of the most attractive targets. Compared with traditional therapies, the emerging PD-1/PD-L1 blockade immunotherapy exhibited more satisfactory curative effects and lower toxicity for patients with advanced head and neck squamous cell carcinoma (HNSCC). This review analyzes the expression characteristics and clinical significance of PD-1/PD-L1 in HNSCC, the immunosuppressive roles of tumor cell and stromal cell expressing PD-1/PD-L1 in this disease, and presents the development landscape of PD-1/PD-L1 inhibitors, which may provide new curative alternatives for recurrent or metastatic HNSCC.
在过去的 10 年中，癌症免疫疗法在多种癌症类型中取得了重大进展，并逐渐应用于临床癌症治疗，其中程序性细胞死亡蛋白 1（PD-1）/程序性细胞死亡配体 1（PD-L1）途径是最有吸引力的靶点之一。与传统疗法相比，新兴的 PD-1/PD-L1 阻断免疫疗法对晚期头颈部鳞状细胞癌（HNSCC）患者显示出更令人满意的疗效和更低的毒性。本文分析了 PD-1/PD-L1 在 HNSCC 中的表达特征和临床意义，肿瘤细胞和基质细胞表达 PD-1/PD-L1 在该疾病中的免疫抑制作用，并介绍了 PD-1/PD-L1 抑制剂的发展前景，为复发性或转移性 HNSCC 提供了新的治疗选择。
Front Immunol. 2020
Curr Opin Oncol. 2019-5
Front Dent Med. 2023-3-13
Oncol Rep. 2024-10
Biomolecules. 2024-7-30
Oral Oncol. 2019-11-1
Zotero 插件